SPECTRUM PHARMACEUTICALS INC Form 8-K December 19, 2013

#### **UNITED STATES**

#### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

**Current Report** 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 19, 2013

#### SPECTRUM PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of 001-35006 (Commission 93-0979187 (I.R.S. Employer

incorporation or organization)

File Number) 11500 S. Eastern Ave., Ste. 240 **Identification No.**)

#### Edgar Filing: SPECTRUM PHARMACEUTICALS INC - Form 8-K

#### Henderson, NV 89052

#### (Address of principal executive offices, zip code)

#### Registrant s telephone number, including area code: (702) 835-6300

#### Former name or former address, if changed since last report: N/A

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Item 9.01 Financial Statements and Exhibits.

Attached hereto as Exhibit 23.2 is the updated consent of Ernst & Young, LLP relating to the Registration Statement on Form S-3 (File No. 333-190413) filed by Spectrum Pharmaceuticals, Inc. on August 6, 2013.

(d) Exhibits.

# Exhibit No.Description23.2Consent of Ernst & Young, LLP, Independent Registered Public Accounting Firm.

#### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 19, 2013

#### SPECTRUM PHARMACEUTICALS, INC.

By: /s/ Kurt A. Gustafson Kurt A. Gustafson

Executive Vice President and Chief Financial Officer

### EXHIBIT INDEX

## Exhibit No. Description

23.2 Consent of Ernst & Young, LLP, Independent Registered Public Accounting Firm.